INTRODUCTION
The insulin-like growth factor (IGF) and its family play a key role in the growth and development of normal tissue and regulate a wide range of biological functions, such as cell proliferation, differentiation, and apoptosis, through paracrine and autocrine mechanisms [1] . In particular, IGF receptor-mediated initiation of signal transduction also activates important intracellular signal pathways in solid tumors, including the Ras/Raf/mitogen-activated protein kinase and phosphoinositide 3-kinase pathway [2] . Previous studies have shown that an increased expression of IGF or its family is associated with the grade of tumor growth and the prognosis for various solid tumors [3] [4] [5] [6] .
Recently, the targeting for IGF has emerged as an important solution for the resistance that arises after targeted treatment.
Gastrointestinal stromal tumors (GISTs) represent a heterogenous group of tumors that originate from the interstitial cells of Cajal in the nerve plexus of the muscularis in the gastrointestinal wall [7] . GISTs are characterized by KIT and platelet-derived growth factor alpha (PDGFRA) receptor abnormalities that represent the key oncogenic event, as well as the most important therapeutic target [8] .
Recently, IGF or its family has emerged as a novel molecular signaling pathway other than KIT and PDGFRA on GISTs [9] . The expression of IGF-1 and IGF-2 family has also been shown to be correlated with a poor prognosis for GISTs [10] . In addition, epidemiologic studies have indicated that high plasma IGF-1 plays a role in energy balance, which has also been shown to influence risk for solid tumors including GIST [11] . Thus, given these results, IGF or its family would seem to play an important role in tumor growth and spread, thereby affecting the prognosis for GISTs.
Single nucleotide polymorphisms (SNPs) have already been widely implicated in cancer development, prognosis, and treatment response, yet similar evidence is lacking for IGF genes. Although IGF-1 tag SNPs have been associated with circulating IGF-1 levels, the functional polymorphisms that might be mediating these associations have not been identified [12] . Wong et al. [13] reported that a putative regulatory IGF-1 in the promoter region is associated with reduced colorectal cancer risk. In addition, IGF-1 haplotype and the IGF2 Ex4-233 C/T polymorphism was also found to be significantly associated with risk of pancreatic cancer [14] .
To date, only a few studies have been published in regards with the relationship between the SNP of IGF or its family gene and clinical outcomes of GISTs. Therefore, the present study analyzed five IGF-1 and IGF-2 gene polymorphisms and their effect on the prognosis for GIST patients.
METHODS

Study population
All the tissues investigated in this study were obtained from 213 consecutive Korean patients who underwent surgical resection between January 1998 and June 2008 at five medical centers. The GIST risk stratification was classified according to the National Institutes of Health (NIH) consensus classification system [7] . Retrospective information was also received concerning the patient characteristics and the date of diagnosis, relapse, and death.
Written informed consent for gene expression analyses was received from the patients, and the study was approved by the Institutional Review Board at Kyungpook National University Hospital (KNUH).
Selection of target IGF-1/2 gene polymorphisms
Due to high number of SNPs in the human genome, the initial challenge was the efficient selection of the SNPs most likely to contribute phenotypic effects. Thus, a prioritizing strategy was created using public databases that provide diverse information on the potential phenotypic risks of SNPs. First candidate genes involved in IGF and related information were collected from web-based databases that included information on the biologic pathway and potential biologic effects of polymorphisms. Next, SNPs with frequencies lower than 0.1 were excluded based on the allele frequencies recorded for East Asian populations obtained from FASTSNP (function analysis and selection tool for SNP). The selected SNPs were then scored according to certain phenotypic risks and ordered according to the sum of risk scores based on the algorithm suggested in a previous report [15] . Finally, and four IGF-1 (＋2995C/A, ＋533C/T, IVS2-16540A/G, Ex4-177G/C) and one IGF-2 (IVS1＋1280A/G) gene polymorphisms were included in the current analysis.
Genotyping of IGF-1 and IGF-2 gene polymorphisms
The genomic DNA was extracted from paraffin-embedded tissue, and four IGF-1 (＋2995C/A, ＋533C/T, IVS2-16540A/G, Ex4-177G/C) and one IGF-2 (IVS1＋ 1280A/G) gene polymorphisms were determined using a Sequenom MassARRAY system. The genotyping was un-thesurgery.or.kr
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SNP, single nucleotide polymorphisms; UEP, unique-event polymorphism. Table 1 .
Statistical analysis
The genotypes for each SNP were analyzed as a threegroup categorical variable (reference model) and grouped according to the dominant and recessive model. The survival estimates were calculated using the Kaplan-Meier method. The differences in overall survival (OS) or relapse-free survival (RFS) according to the gene polymorphisms were compared using log-rank tests. For the multivariate analysis, Cox's proportional hazard regression model was used for the survival analyses. The analyses were adjusted for age, gender, primary site of disease, pathology, and risk stratification. The hazard ratio and 95% confidence interval were also estimated. A cut-off P-value of 0.05 was adopted for all the statistical analyses.
All the analyses were performed using the SPSS ver. 14 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Patient characteristics and survival analysis
The patient characteristics are shown in Table 2 Table 3 .
With a median follow-up duration of 18.4 months, 28 relapses (13.1%) were documented and 14 patients died. The estimated 5-year RFS and OS rates were 69.9% and 86.7%, respectively (Fig. 1) . Plus, the survival differed according the NIH consensus classification system (OS, P = 0.046; RFS, P ＜ 0.001) (Fig. 2) .
Genotype frequency effect on survival
The five IGF-1 and IGF-2 gene polymorphisms were successfully amplified in all cases. The frequencies of each genotype are shown in Table 4 and conformed to the 
DISCUSSION
The prognostic impact of five SNPs of the IGF and IGF-2 gene was investigated in patients with a surgically resected GIST. However, no significant association was observed between the five polymorphisms and survival in these patients. Given the homogenous ethnic background of Korean patients, any potential confounding effect due to ethnicity was likely to be small in the present study.
Since IGF or its family plays a critical role in tumor-related growth and metastasis, the association of IGF gene polymorphisms with the risk or prognosis of several solid tumors, such as liver, prostate, pancreas, and breast cancer has already been demonstrated [12, 14, [16] [17] [18] [19] . Recently, the current authors also reported that IGF gene polymorphisms are no significant association with survival in patients with colorectal cancer [20] . Although no data has thesurgery.or.kr Vashist et al. [21] reported that haeme oxygenase-1 promotor GTn polymorphism was a potential prognostic marker.
In the previous studies, polymorphic variants of the [24, 25] . These studies implicate IGF-1 receptor as a potential therapeutic target in these patients with GIST.
The present study also evaluated a SNP of IGF-2 gene, thesurgery.or.kr yet it was not found to have a significant influence on the prognosis of GIST. In a previous study by Suzuki et al. [14] that compared the frequency of 6 SNPs of IGF-1 and IGF-2 in a large-scale case control study to determine whether genetic variations of IGF modify pancreatic cancer risk, the IGF-2 3'-UTR Ex4 -233T/T genotype was significantly associated with a reduced risk of pancreatic cancer. In contrast, Lai et al. [22] 
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